Investor Relations

Press Releases

Date Title and Summary View
Toggle Summary Mylan to Bring a Biosimilar of BOTOX to the Market Through a Collaboration and License agreement with Revance Therapeutics
View HTML
Toggle Summary Revance Therapeutics to Release Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 28, 2018
Conference Call Scheduled for Wednesday, February 28, 2018 at 4:30pm ET NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the
View HTML
Toggle Summary Revance to Participate in the RBC Capital Markets 2018 Global Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the company will participate in the RBC Capital Markets 2018 Global Healthcare
View HTML
Toggle Summary Pivotal SAKURA Phase 3 Clinical Data to be Presented at IMCAS World Congress 2018
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced presentation of clinical data from the company's two pivotal SAKURA Phase 3 trials of
View HTML
Toggle Summary Revance Announces Interim Phase 2a Results for RT002 in Treating Plantar Fasciitis
  NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced interim 8-week Phase 2a results for its next-generation neuromodulator
View HTML
Toggle Summary Revance Provides Update on Anticipated Clinical Milestones and Financial Outlook for 2018
- Reports 2017 Unaudited Year-End Cash and Investments Balance Exceeded $280 million - - Expects to Complete RT002 SAKURA Phase 3 Program and Start RT002 Phase 3 Trial for Cervical Dystonia in 2018 - - Plantar Fasciitis Phase 2a Interim Results by Mid-January - NEWARK, Calif.
View HTML
Toggle Summary Revance Announces Closing of Public Offering of Common Stock
Gross Proceeds of Offering Total $167.1 Million NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced the
View HTML
Toggle Summary Revance Announces Pricing of Public Offering of Common Stock
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced the pricing of an underwritten public offering of
View HTML
Toggle Summary Revance Announces Proposed Public Offering of Common Stock
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced a proposed underwritten public offering in which it will
View HTML
Toggle Summary Revance's RT002 Meets Primary and All Secondary Endpoints, Achieves 6-Month Duration in Pivotal SAKURA Phase 3 Trials for Glabellar Lines
- Highly statistically significant results on primary composite endpoint achieved at Week 4 - - RT002 delivered highly statistically significant reduction in severity of glabellar lines at Week 24 - - If approved, RT002 could represent a new, next-generation, long-acting neuromodulator - - Revance
View HTML
Shareholder Tools Request Printed Materials Request Email Alerts Download Library RSS News Feeds Share this Page Search Investor Site
Shareholder Tools